252 related articles for article (PubMed ID: 35459366)
21. [Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature].
Adam Z; Szturz P; Krejčí M; Koukalová R; Michalková E; Řehák Z; Pourová E; Pour L; Volfová P; Sandecká V; Čermáková Z; Křen L; Sokol F; Hanke I; Penka I; Petrášová H; Ševčíková S; Král Z; Mayer J
Vnitr Lek; 2016 Apr; 62(4):287-98. PubMed ID: 27250606
[TBL] [Abstract][Full Text] [Related]
22. The Role of Radiation Therapy in Unicentric Castleman Disease: A Case Report.
Rodriguez C; Rivera Rubi L; Menjivar O; Suazo J
Cureus; 2023 Nov; 15(11):e49687. PubMed ID: 38161935
[TBL] [Abstract][Full Text] [Related]
23. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
[TBL] [Abstract][Full Text] [Related]
24. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
[TBL] [Abstract][Full Text] [Related]
25. Long-term treatment outcome of Castleman's disease: A real-world experience.
Min GJ; Jeon YW; Kim TY; Kwag DH; Lee JH; Lee JY; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Cho SG
Front Oncol; 2022; 12():974770. PubMed ID: 35992883
[TBL] [Abstract][Full Text] [Related]
26. Unicentric Castleman Disease.
Wong RSM
Hematol Oncol Clin North Am; 2018 Feb; 32(1):65-73. PubMed ID: 29157620
[TBL] [Abstract][Full Text] [Related]
27. The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease.
Horna P; King RL; Jevremovic D; Fajgenbaum DC; Dispenzieri A
Haematologica; 2023 Jan; 108(1):207-218. PubMed ID: 35484648
[TBL] [Abstract][Full Text] [Related]
28. Treatment and Outcome of Castleman Disease: A Retrospective Report of 31 Patients.
Tang D; Guo Y; Tang Y; Wang H
Ther Clin Risk Manag; 2022; 18():499-509. PubMed ID: 35502435
[TBL] [Abstract][Full Text] [Related]
29. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
Lang E; Sande B; Brodkin S; van Rhee F
Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
[TBL] [Abstract][Full Text] [Related]
30. A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.
Plano F; Mancuso S; Camarda GM; Butera MG; Sucato G; Alecci G; Florena AM; Perrone S; Siragusa SM
Chemotherapy; 2024; 69(1):35-39. PubMed ID: 37634492
[TBL] [Abstract][Full Text] [Related]
31. Castleman disease: Experience from a single institution.
Abraham SS; Narayanan G; Thambi SM; Vasudevan JA; Joy Philip DS; Purushothaman PN; Nair SG; Nair R
Med Int (Lond); 2023; 3(6):56. PubMed ID: 37927353
[TBL] [Abstract][Full Text] [Related]
32. The role of interleukin 6 in the pathogenesis and therapy of Castleman disease - an immunologist's perspective.
Milota T; Střížová Z; Sobotková M; Bartůňková J
Cas Lek Cesk; 2023; 162(2-3):106-111. PubMed ID: 37474295
[TBL] [Abstract][Full Text] [Related]
33. Clinical, laboratory and imaging findings in Castleman's disease - The subtype decides.
Haap M; Wiefels J; Horger M; Hoyer A; Müssig K
Blood Rev; 2018 May; 32(3):225-234. PubMed ID: 29223447
[TBL] [Abstract][Full Text] [Related]
34. Overview of Castleman disease.
Dispenzieri A; Fajgenbaum DC
Blood; 2020 Apr; 135(16):1353-1364. PubMed ID: 32106302
[TBL] [Abstract][Full Text] [Related]
35. Castleman disease: A single-center case series.
Pribyl K; Vakayil V; Farooqi N; Arora N; Kreitz B; Ikramuddin S; Linden MA; Harmon J
Int J Surg Case Rep; 2021 Mar; 80():105650. PubMed ID: 33631648
[TBL] [Abstract][Full Text] [Related]
36. Idiopathic multicentric Castleman's disease: a systematic literature review.
Liu AY; Nabel CS; Finkelman BS; Ruth JR; Kurzrock R; van Rhee F; Krymskaya VP; Kelleher D; Rubenstein AH; Fajgenbaum DC
Lancet Haematol; 2016 Apr; 3(4):e163-75. PubMed ID: 27063975
[TBL] [Abstract][Full Text] [Related]
37. [Clinical Features and Prognosis of Patients with Castleman's Disease].
Huang XJ; Zhang XL; Wei XF; Liang XQ; Fu Y; Zhao YY; Li QF; Zhang QK; Feng YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):135-140. PubMed ID: 36765490
[TBL] [Abstract][Full Text] [Related]
38. The role of surgical resection in Unicentric Castleman's disease: a systematic review.
Mitsos S; Stamatopoulos A; Patrini D; George RS; Lawrence DR; Panagiotopoulos N
Adv Respir Med; 2018; 86(1):36-43. PubMed ID: 29490420
[TBL] [Abstract][Full Text] [Related]
39. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
Pierson SK; Lim MS; Srkalovic G; Brandstadter JD; Sarmiento Bustamante M; Shyamsundar S; Mango N; Lavery C; Austin B; Alapat D; Lechowicz MJ; Bagg A; Li H; Casper C; van Rhee F; Fajgenbaum DC
Blood Adv; 2023 Nov; 7(21):6652-6664. PubMed ID: 37656441
[TBL] [Abstract][Full Text] [Related]
40. A retrospective study of 44 patients with head and neck Castleman's disease.
Wang T; Chen X; Chen W; Shi L; Liu J
Eur Arch Otorhinolaryngol; 2022 May; 279(5):2625-2630. PubMed ID: 34480599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
